Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02204098 · ClinicalTrials.gov registry record · Phase 1

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

A Phase 1 study of Breast Cancer and Breast Carcinoma, sponsored by Washington University School of Medicine.

Active
Registry status
Phase 1
Development phase
27
Enrollment target
1
Study location

NCT02204098 is a Phase 1 study of Breast Cancer and Breast Carcinoma that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 27 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02204098, a Phase 1 study of Breast Cancer and Breast Carcinoma, is active but no longer recruiting, sponsored by Washington University School of Medicine.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to find out about the safety of injecting the gene (DNA) for mammaglobin-A into people with breast cancer. The DNA used in this study was purified from bacteria and contains the gene for mammaglobin-A. Mammaglobin-A is a protein that is highly expressed by breast cancer cells. Injection of mammaglobin-A DNA may be a way to generate an immune response to breast cancer cells. There is evidence that an immune response may be a way to fight cancer. In addition to evaluating the safety of the mammaglobin-A injection, this study is also looking at the immune response that the participant's body has after each injection.

Conditions Studied

Breast Cancer Breast Carcinoma Malignant Neoplasm of Breast

Interventions

  • BIOLOGICAL Mammaglobin-A DNA Vaccine
  • PROCEDURE Optional biopsy

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2015-01-07
Est. Completion 2028-08-31
Phase Phase 1

Sponsor

Washington University School of Medicine

1,502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02204098

The ClinicalTrials.gov registry entry for NCT02204098 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Mammaglobin-A DNA Vaccine is the first listed.

NCT02204098 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT02204098 about?

NCT02204098 is a clinical study titled "Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy". The purpose of this research study is to find out about the safety of injecting the gene (DNA) for mammaglobin-A into people with breast cancer. The DNA used in this study was purified from bacteria and contains the gene for mammaglobin-A. Mammaglobin-A is a protein that is highly expressed by breas...

What is the current status of trial NCT02204098?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-01-07. Estimated completion is 2028-08-31.

What conditions does trial NCT02204098 study?

This clinical trial studies the following conditions: Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast.

What interventions are being tested in trial NCT02204098?

The interventions under investigation include: Mammaglobin-A DNA Vaccine (BIOLOGICAL), Optional biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT02204098?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02204098 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Breast Carcinoma

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.